Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy-Reference-Cited by-同舟云学术

Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy

Published:2020-08-26 Issue:19 Volume:63 Page:11286-11301
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Haixia¹,Chen Daoyuan²,Zhan Siyue¹,Wu Weijian¹,Xu Huiying¹,Luo Chunxiang¹,Su Hui¹,Feng Yanqiao¹,Shao Weiyan¹,Wan Arabella³,Zhou Binhua¹⁴,Wan Guohui¹⁵^ORCID,Bu Xianzhang¹^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China

2. Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Guangzhou 519041, China

3. Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China

4. School of Chinese Pharmacy, Guizhou Minzu University, Guiyang 550025, China

5. National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, National Engineering Research Center for New Drug and Druggability (Cultivation), Sun Yat-Sen University, Guangzhou 510006, China

Funder

Guangdong Science and Technology Department

Guangzhou Science and Technology Program key projects

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01262

Reference44 articles.

1. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules